Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
BMC Cancer|March 18, 2022
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysisZe-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, et al.
The Lancet. Infectious Diseases|November 26, 2015
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyYi-Yun Liu, Yang Wang, Timothy R Walsh, et al.
Emerging Microbes & Infections|February 15, 2021
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune responseChun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, et al.
Lancet (London, England)|August 24, 2010
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialFeng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, et al.
The Lancet Regional Health. Western Pacific|September 8, 2025
Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trialGuo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trialZhao-Jun Mo, Shou-Jie Huang, Ling-Xian Qiu, et al.
The Lancet. Infectious Diseases|April 13, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trialHong-Xing Pan, Ling-Xian Qiu, Qi Liang, et al.
Pageof 6